Content about Stimulants

September 30, 2010
Mylan's generic Wellbutrin XL enters market

Mylan has launched a generic version of a common antidepressant, the company said Friday....

PITTSBURGH Mylan has launched a generic version of a common antidepressant, the company said Friday.

 

Mylan announced the launch of bupropion hydrochloride extended-release tablets in the 150-mg and 300-mg strengths, a once-daily treatment for depression.

 

 

The drug is a generic version of GlaxoSmithKline’s Wellbutrin XL. Various versions of the drug had sales of around $752 million during the 12-month period ended in June, according to IMS Health.

 

August 22, 2010
Industry voices support for meth act

The industry-supported Combat Meth-amphetamine Enhancement Act, H.R. 2923, passed muster at the House Committee on...

July 20, 2010
Caraco launches generic Wellbutrin SR

Generic drug maker Caraco Pharmaceutical Labs has launched a generic antidepressant, Caraco said Wednesday....

DETROIT Generic drug maker Caraco Pharmaceutical Labs has launched a generic antidepressant, Caraco said Wednesday.

 

The drug maker announced the launch of bupropion hydrochloride extended-release tablets in the 150 mg and 200 mg strengths.

 

 

The drug is a generic version of GlaxoSmithKline’s Wellbutrin SR. Various versions of the drug have annual sales of $300 million, according to Caraco.

 

July 20, 2010
FDA approves additional strengths of Actavis' generic Wellbutrin SR

Actavis has received regulatory approval from the Food and Drug Administration for a generic antidepressant,...

MORRISTOWN, N.J. Actavis has received regulatory approval from the Food and Drug Administration for a generic antidepressant, the drug maker announced Wednesday.

Actavis said it immediately will begin distributing its bupropion HCl extended-release (SR) tablets in 100-mg and 200-mg strengths. The drug is the generic equivalent of GlaxoSmithKline's Wellbutrin SR. Actavis already has marketed generic Wellbutrin SR in the 150-mg strength. The drug maker received approval in March 2008.

July 8, 2010
FDA issues warning about Que She weight-loss supplement

The Food and Drug Administration on Thursday warned that Que She, marketed as an herbal...

July 6, 2010
FDA approves expanded use of Daytrana

The Food and Drug Administration has approved a drug made by Shire for treating attention...

May 16, 2010
Congress heats up e-tracking debate to fight meth cooks

Electronic tracking or prescription-only? That’s the question that vexed Congressional leaders last month as they...

May 3, 2010
Mylan gets regulatory approval for generic Zyban

The Food and Drug Administration has approved Mylan’s generic version of a smoking-cessation drug, Mylan...

March 29, 2010
FTC wins pay-for-delay battle

The Federal Trade Commission’s crusade against patent settlements between branded and generic drug makers moved...

March 29, 2010
Jet lag treatment receives complete response letter

The Food and Drug Administration declined to approve a Cephalon drug as a treatment for...

March 8, 2010
Missouri selects NPLEx e-tracking program to block PSE sales

Missouri has selected the National Precursor Log Exchange to serve as its statewide, real-time electronic...

March 3, 2010
Shire given market exclusivity for ADHD drug

The U.S. District Court for the District of Columbia has upheld a decision by the...

February 20, 2010
Watson seeks FDA approval for depression generic

Watson Pharmaceuticals has filed a regulatory approval application with the Food and Drug Administration for...

January 21, 2010
Mississippi legislators seek to reverse-switch PSE products

Four Mississippi legislators earlier this month added the Magnolia State as one of those states...

January 10, 2010
Mylan confirms first-to-file patent challenge for Nuvigil generic

Drug maker Cephalon and its French subsidiary sued generic drug maker Mylan in connection with...

January 5, 2010
Watson seeks FDA approval for sleep disorder treatment

Watson has filed an abbreviated new drug application for the generic version of a sleep...

November 19, 2009
NADDI cracks down on methamphetamine with new initiative

In a nutshell, this program gives any legislative body — state or local — debating...

NEW YORK In a nutshell, this program gives any legislative body — state or local — debating around whether a prescription ought to be required in the purchase of a pseudoephedrine product one less reason to pull the trigger on that decision. And it’s a pretty big reason. Before, the argument could be made that implementing a program like NPLEx was prohibitive because of the associated cost.

October 18, 2009
Report: Union, Mo., passes new PSE legislation

There is a big danger here, and it’s a danger that has less to do...

NEW YORK There is a big danger here, and it’s a danger that has less to do with the neighborhood meth addict in search of pseudoephedrine, and more to do with appropriate access to medicines and who gets to be the gatekeeper to that access. Because not only will a prescription-only PSE restrict consumer access to a legitimate nonprescription cough-cold ingredient, but if successfully mandated by the local government, it also has the potential to limit legitimate access to just about any cost-saving OTC medicine and for just about any reason.

 

July 19, 2009
Washington, Mo., government votes to move PSE products to Rx-only

In the short term, it means pharmacists operating out of one of the 12 or...

NEW YORK In the short term, it means pharmacists operating out of one of the 12 or so pharmacies in Washington, Mo., will need to see a doctor’s prescription before filling any pseudoephedrine requests.

February 28, 2007
ECRM Cough/Cold 2007

The most significant event that occurred during a soft 2006-2007 cough-and-cold season was the shift of the decongestant pseudoephedrine behind the counter in all 50 states. To be sure, some states still require more strict regulations on the sale of PSE, but at least now PSE is behind the counter in a legislative effort to thwart homegrown methamphetamine makers.

The most significant event that occurred during a soft 2006-2007 cough-and-cold season was the shift of the decongestant pseudoephedrine behind the counter in all 50 states. To be sure, some states still require more strict regulations on the sale of PSE, but at least now PSE is behind the counter in a legislative effort to thwart homegrown methamphetamine makers. Click below to download the PDF of ECRM Cough/Cold 2007.